- Home
- OMER vs WDI Comparison
OMER vs WDI Comparison
Compare OMER & WDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OMER | WDI |
|---|---|---|
| Founded | 1994 | 2021 |
| Country | United States | United States |
| Employees | 202 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 788.4M | 732.4M |
| IPO Year | 2008 | N/A |
Fundamental Metrics
Financial Performance| Metric | OMER | WDI |
|---|---|---|
| Price | $10.95 | $13.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $32.50 | N/A |
| AVG Volume (30 Days) | ★ 713.1K | 197.2K |
| Earning Date | 03-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.80% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.12 |
| Revenue | ★ $29,868,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $11.88 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.95 | $13.22 |
| 52 Week High | $17.65 | $15.28 |
Technical Indicators
Market Signals| Indicator | OMER | WDI |
|---|---|---|
| Relative Strength Index (RSI) | 42.16 | 27.57 |
| Support Level | $10.55 | N/A |
| Resistance Level | $11.93 | $14.03 |
| Average True Range (ATR) | 0.45 | 0.20 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 24.24 | 1.99 |
Price Performance
Historical ComparisonAbout OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About WDI Western Asset Diversified Income Fund of Beneficial Interest
Western Asset Diversified Income Fund is a newly-organized, diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income.